Global Intraperitoneal Needle Market Size By Type (Stainless Steel Needles, Plastic Needles), By Application (Hospitals And Clinics, Diagnostic Centers), By Region, And Segment Forecasts, 2023 to 2032

The Global Intraperitoneal Needle Market was valued at USD 142 million in 2023 and is projected to reach USD 245 million by 2031, growing at a CAGR of 7.1% during the forecast period from 2023 to 2031. The market's expansion is fueled by the increasing incidence of peritoneal cancers, growing adoption of intraperitoneal chemotherapy, advancements in minimally invasive surgical techniques, and the rising demand for targeted drug delivery systems. Intraperitoneal needles play a crucial role in delivering chemotherapy agents directly into the peritoneal cavity, offering enhanced efficacy and fewer systemic side effects compared to intravenous administration.

Drivers:

1. Rising Cancer Burden and Chemotherapy Demand:

The global increase in peritoneal and ovarian cancers, especially in aging populations, is significantly driving demand for effective chemotherapy methods. Intraperitoneal needle systems facilitate local and potent drug delivery, improving therapeutic outcomes.

2. Advances in Minimally Invasive Procedures:

Technological improvements in minimally invasive surgical equipment have enabled safer, more precise insertion of intraperitoneal needles. These procedures are being increasingly preferred due to reduced recovery times and fewer complications.

3. Favorable Clinical Guidelines:

Organizations such as the National Comprehensive Cancer Network (NCCN) continue to recommend intraperitoneal chemotherapy for certain cancers, boosting market growth.

Restraints:

1. Procedural Complexity and Risks:

Intraperitoneal chemotherapy involves potential complications such as infection, catheter-related issues, and peritonitis. These factors limit widespread adoption, particularly in settings with limited healthcare infrastructure.

2. Limited Patient Eligibility:

Not all cancer patients qualify for intraperitoneal therapy due to disease stage or pre-existing conditions. This reduces the addressable market size.

Opportunity:

1. Growing Application in Post-Surgical Drug Delivery:

There is increasing interest in using intraperitoneal needles for post-operative drug administration, including antibiotics and pain relief, which opens new clinical use cases beyond oncology.

2. Expanding Healthcare Access in Developing Nations:

Improved healthcare infrastructure and awareness in emerging economies present untapped opportunities for market expansion, particularly in oncology-focused hospitals and specialty clinics.

Market by System Type Insights:

By system type, Straight Bevel Tip Intraperitoneal Needles accounted for the largest market share in 2023 due to their ease of insertion and wide clinical adoption. These needles offer precise targeting and reduce trauma during insertion. However, Curved and Safety-Engineered Needle Designs are expected to experience the fastest growth due to enhanced safety features and surgeon preference in minimally invasive procedures.

Market by End-use Insights:

Based on end-use, Hospitals dominated the global market in 2023, holding more than 55% of the market share. Their integrated oncology and surgical care systems make them ideal for intraperitoneal therapy. The Ambulatory Surgical Centers (ASCs) segment is expected to register notable growth, driven by a rising number of outpatient cancer procedures and increased reimbursement support.

Market by Regional Insights:

Geographically, North America led the global intraperitoneal needle market in 2023, driven by high cancer incidence rates, advanced healthcare infrastructure, and early adoption of new therapeutic techniques. Asia-Pacific is projected to witness the highest growth rate during the forecast period, supported by increasing cancer awareness, expanding oncology care access, and government-backed healthcare reforms in countries like China and India.

Competitive Scenario:

Leading players in the Global Intraperitoneal Needle Market include Becton, Dickinson and Company, Smiths Medical, Cardinal Health, Terumo Corporation, B. Braun Melsungen AG, Medline Industries, and AngioDynamics. These companies are investing in R&D for advanced needle designs, safety innovations, and market-expanding partnerships. For instance:

In 2023, BD launched a next-gen intraperitoneal needle with improved ergonomics and flow control for enhanced drug delivery.

In 2024, Terumo introduced an integrated infusion system designed for optimized peritoneal chemotherapy, minimizing drug leakage risks.

In 2025, Cardinal Health expanded its oncology supply division to include customizable intraperitoneal delivery kits, enhancing procedural efficiency for hospitals.

Scope of Work – Global Intraperitoneal Needle Market

Report Metric Details

Market Size (2023) USD 142 million

Projected Market Size (2031) USD 245 million

CAGR (2023–2031) 7.1%

Market Segments System Type (Straight, Curved, Safety), End-use (Hospitals, ASCs, Clinics), Region

Growth Drivers Rising cancer prevalence, advancements in minimally invasive techniques, favorable clinical guidelines

Opportunities Post-surgical drug delivery, emerging market expansion

Key Market Developments:

2023: BD introduced a dual-lumen intraperitoneal needle with backflow prevention, aimed at reducing leakage during administration.

2024: Smiths Medical unveiled a flexible, ergonomic design for better navigation during laparoscopic procedures.

2025: AngioDynamics partnered with oncology networks in Europe to deploy intraperitoneal therapy kits tailored to patient-specific regimens.

FAQs:

1) What is the current market size of the Global Intraperitoneal Needle Market?

The market size was valued at USD 142 million in 2023.

2) What is the major growth driver of the Global Intraperitoneal Needle Market?

The primary driver is the increasing adoption of intraperitoneal chemotherapy in cancer treatment protocols.

3) Which is the largest region during the fo